TY - JOUR
T1 - Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma
AU - Kufukihara, Ryohei
AU - Tanaka, Nobuyuki
AU - Takamatsu, Kimiharu
AU - Niwa, Naoya
AU - Fukumoto, Keishiro
AU - Yasumizu, Yota
AU - Takeda, Toshikazu
AU - Matsumoto, Kazuhiro
AU - Morita, Shinya
AU - Kosaka, Takeo
AU - Aimono, Eriko
AU - Nishihara, Hiroshi
AU - Mizuno, Ryuichi
AU - Oya, Mototsugu
N1 - Funding Information:
This study was supported by Grants-in-Aid for Scientific Research (KAKENHI 19K18598 and 21K09356 to RK; 19H03792, 21K19414, and 22H03217 to NT; and 18H02939 to MO) and grants from the Kobayashi Foundation for Cancer Research (to NT), the SGH Foundation for Cancer Research (to NT), the JUA Research Grant (to NT), the Princess Takamatsu Cancer Research Fund (to NT), and the Keio Gijuku Academic Development Funds (to NT).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/10/5
Y1 - 2022/10/5
N2 - Background: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. Methods: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. Results: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. Conclusion: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.
AB - Background: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. Methods: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. Results: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. Conclusion: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.
UR - http://www.scopus.com/inward/record.url?scp=85133041616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133041616&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01895-3
DO - 10.1038/s41416-022-01895-3
M3 - Article
C2 - 35764788
AN - SCOPUS:85133041616
SN - 0007-0920
JO - British Journal of Cancer
JF - British Journal of Cancer
ER -